Overview

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+).
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.